Cedrik M. Britten
Chief Tech/Sci/R&D Officer bei IMMATICS N.V.
Vermögen: 2 Mio $ am 31.03.2024
Profil
Cedrik M.
Britten is currently the Chief Medical Officer at Immatics Biotechnologies GmbH and Immatics NV.
Prior to his current positions, he worked as the VP & Head-Oncology Cell Therapy Research at GSK Plc from 2015 to 2020 and as the Vice President-Research & Development at BioNTech RNA Pharmaceuticals GmbH from 2010 to 2015.
Britten received his graduate and doctorate degrees from The Johannes Gutenberg University of Mainz.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
IMMATICS N.V.
0,22% | 31.01.2024 | 227 735 ( 0,22% ) | 2 Mio $ | 31.03.2024 |
Aktive Positionen von Cedrik M. Britten
| Unternehmen | Position | Beginn |
|---|---|---|
| IMMATICS N.V. | Chief Tech/Sci/R&D Officer | 01.06.2020 |
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Chief Tech/Sci/R&D Officer | 01.06.2020 |
Ehemalige bekannte Positionen von Cedrik M. Britten
| Unternehmen | Position | Ende |
|---|---|---|
| GSK PLC | Corporate Officer/Principal | 01.05.2020 |
BioNTech RNA Pharmaceuticals GmbH
 BioNTech RNA Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Part of BioNTech SE, BioNTech RNA Pharmaceuticals GmbH develops immunotherapies to revolutionize the treatment of cancer and other diseases. The private company is based in Mainz, Germany. | Chief Tech/Sci/R&D Officer | 01.01.2015 |
Ausbildung von Cedrik M. Britten
| The Johannes Gutenberg University of Mainz | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| GSK PLC | Health Technology |
| IMMATICS N.V. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
BioNTech RNA Pharmaceuticals GmbH
BioNTech RNA Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Part of BioNTech SE, BioNTech RNA Pharmaceuticals GmbH develops immunotherapies to revolutionize the treatment of cancer and other diseases. The private company is based in Mainz, Germany. | Health Technology |
